Source disclosure: February 12, 2026
Immuno-Biological Laboratories Co., Ltd. [4570.T]
TOKYO, Feb 18 (Pulse News Wire) – Immuno-Biological Laboratories Co., Ltd. (4570.T) reported consolidated results for Q3 FY2026 (ending March 2026).
1% YoY). 1%). net profit attributable to shareholders was ¥248 million (+86.1%).
08 billion with an equity ratio of 84.5%. For the next fiscal year, the company forecasts 02 billion (+5.7%).
Note: Financial figures from the earnings presentation have been removed pending correction. For accurate figures, refer to the company's earnings summary (kessan tanshin) filed separately on TDNet.
AI-translated content. 🟢 Confidence: High See terms •Financial results — FY2026/3 (consolidated)
| Metric | Current | YoY |
|---|---|---|
| Revenue | ¥742M | +9.1% |
| Operating profit | ¥223M | +79.1% |
| Net profit | ¥248M | +86.1% |
Next period forecast
Revenue
¥1,025M
+5.7%Op. profit
¥240M
+14.6%Net profit
¥265M
+6.4%Source: TDNet filing · Figures in millions of yen